iOnctura strives to develop differentiated and targeted therapeutic strategies based on the latest scientific insights. Through its strong collaborations with Cancer Research UK, the NKI (the Netherlands Cancer Institute) and Merck KGaA iOnctura has access to resources, infrastructure and world renowned experts in the field to support and advance its programs quickly for treatment of patients with life-threatening disease.

iOnctura also aims to maximise the potential of its pipeline by selecting the most appropriate combination strategy for each of its molecules, including internal pipeline combinations.

Cancer Research UKMerckDutch Cancer Institute
  • Merck KGaA Darmstadt, Germany
    Have granted privileged access to and supply of Bavencio® (avelumab)*, Pfizer/Merck KGaA’s anti-PD-L1 antibody for early clinical combination studies with checkpoint inhibitors.
  • Cancer Research UK
    Provides research and development expertise and infrastructure through their highly respected Therapeutic Discovery laboratories (CRUK-TDL), also access to a broad network of academic collaborators.
  • The Netherlands Cancer Institute
    Collaboration geographically broadens and deepens iOnctura’s access to opinion-leading academics and R&D expertise.

* Bavencio® (avelumab) is jointly developed by Merck KGaA, Darmstadt, Germany and Pfizer.
Please scroll down to read more about Merck KGaA, Darmstadt, Germany, Cancer Research UK and NKI, the Netherlands Cancer Institute.

Cancer Research UK

Cancer Research UK

Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Their specialist Commercial Partnerships Team work closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners.

The team develop promising ideas into successful cancer therapeutics, software, devices, diagnostics and enabling technologies. This helps to accelerate progress in exciting new discoveries in cancer research and bring new treatments to patients sooner. More information on Cancer Research UK’s Commercial Partnerships Team can be found at

Cancer Research UK’s Therapeutic Discovery Laboratories (CRUK-TDL) is the in-house Cancer Research UK drug discovery unit with a principal focus on establishing and prosecuting biologically-themed multi-project alliances with industry. Their expertise spans cancer target validation and disease positioning, immunology, assay development and HTS, protein crystallography, medicinal chemistry, PK-PD and cancer models. Through their alliance approach, they align these key skills with internationally competitive academic research and the development capabilities of industry partners to maximise cancer patient benefit. More information on CRUK-TDL can be found at

For more information about other areas of Cancer Research UK see:

Dutch Cancer Institute

Netherlands Cancer Institute
(NKI, Nederlands Kanker Instituut)

The Netherlands Cancer Institute was established on October 10, 1913. The founders, Rotgans, professor of Surgery, De Bussy, publisher, and De Vries, professor of Pathology, wanted to create a cancer institute ‘where patients suffering from malignant growths could be treated adequately and where cancer and related diseases could be studied’.

They bought a house on one of the canals in Amsterdam and named it the ‘Antoni van Leeuwenhoek Huis’, after the famous Dutch microscopist. The clinic had room for 17 patients, while the laboratory could accommodate 8 to 10 scientists.

Nowadays, The Netherlands Cancer Institute accommodates approximately 650 scientists and scientific support personnel. The Antoni van Leeuwenhoek Hospital has 185 medical specialists, 180 beds, an out-patients clinic with around 106,000 visits, 12 operating theaters and 11 irradiation units for radiotherapy. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development and training.

By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.